Search Results - V. Diéras

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients?

    Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients? by V. Girre, Marie-Christine Falcou, Mathilde Gisselbrecht, G. Gridel, V. Mosseri, Carole Bouleuc, Rollon Poinsot, Lionel Védrine, Luc Ollivier, Valérie Garabige, J. Y. Pierga, V. Diéras, L. Mignot

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

    Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 by H. S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiß, C.H. Barrios, Hiroji Iwata, V. Diéras, EP Winer, Mark Kockx, Dieter Peeters, Jane Yuet Ching Hui, J. Lin, Anh Nguyen Duc, Giulia Viale, Luciana Molinero, Leisha A. Emens

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

    REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours by Christelle Lévy, Djelila Allouache, Joëlle Lacroix, A. Dugué, S. Supiot, Mario Campone, Marc-André Mahé, Salim Kichou, Marianne Leheurteur, C. Hanzen, V. Diéras, Youlia Kirova, F. Campana, Émilie Le Rhun, L. Gras, T Bachelot, Marie Pierre Sunyach, I. Hrab, Julien Geffrelot, K. Gunzer, Jean‐Marc Constans, Jean‐Michel Grellard, Bénédicte Clarisse, Xavier Paolettí

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Sacituzumab govitecan in metastatic triple-negative breast cancer

    Sacituzumab govitecan in metastatic triple-negative breast cancer by A. Bardia, S.A. Hurvitz, S.M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S.D. Sardesai, K. Kalinsky, A.B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O apos Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L.A. Carey, L. Gianni, M.J. Piccart, S. Loibl, D.M. Goldenberg, Q. Hong, M.S. Olivo, L.M. Itri, H.S. Rugo, ASCENT Clinical Trial Investigators

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer by P. Tarantino, Giulia Viale, Michael F. Press, Xin Hu, Frédérique Penault‐Llorca, A. Bardia, Anna Batistatou, H.J. Burstein, L.A. Carey, Javier Cortés, C. Denkert, V. Diéras, William Jacot, A. Koutras, Alizée Lebeau, S. Loibl, Shanu Modi, M.F. Mosele, Elena Provenzano, Giancarlo Pruneri, Jorge S. Reis‐Filho, Federico Rojo, Roberto Salgado, P. Schmid, Stuart J. Schnitt, S.M. Tolaney, Dario Trapani, A. Vincent-Salomon, A.C. Wolff, George Pentheroudakis, Fabrice André, G. Curigliano

    Published 2023
    Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: